Zacks Investment Research on MSN7d
Puma Biotechnology Stock Rises 35% in 6 Months: Here's WhyShares of Puma Biotechnology PBYI have rallied 35.3% in the past six months against the industry’s decline of 9.2%. The ...
Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical ...
Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical ...
Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback